WO2016183366A3 - Compositions et méthodes permettant l'extinction de l'expression de l'arn du virus de l'hépatite d - Google Patents

Compositions et méthodes permettant l'extinction de l'expression de l'arn du virus de l'hépatite d Download PDF

Info

Publication number
WO2016183366A3
WO2016183366A3 PCT/US2016/032188 US2016032188W WO2016183366A3 WO 2016183366 A3 WO2016183366 A3 WO 2016183366A3 US 2016032188 W US2016032188 W US 2016032188W WO 2016183366 A3 WO2016183366 A3 WO 2016183366A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hepatitis
compositions
virus rna
silencing expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/032188
Other languages
English (en)
Other versions
WO2016183366A2 (fr
Inventor
Amy C. H. Lee
Ian Maclachlan
Nicholas Michael SNEAD
Emily P. THI
Xin Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protiva Biotherapeutics Inc
Original Assignee
Protiva Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protiva Biotherapeutics Inc filed Critical Protiva Biotherapeutics Inc
Publication of WO2016183366A2 publication Critical patent/WO2016183366A2/fr
Publication of WO2016183366A3 publication Critical patent/WO2016183366A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à des compositions qui contiennent des acides nucléiques thérapeutiques, tels qu'un ARNsi, qui ciblent l'expression de l'ARN du virus de l'hépatite D (VHD), des particules lipidiques comprenant un ou plusieurs (par ex., une combinaison) desdits acides nucléiques thérapeutiques, et des méthodes de distribution et/ou d'administration des particules lipidiques (par ex., pour traiter l'infection par le VHD chez l'homme).
PCT/US2016/032188 2015-05-12 2016-05-12 Compositions et méthodes permettant l'extinction de l'expression de l'arn du virus de l'hépatite d Ceased WO2016183366A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562160411P 2015-05-12 2015-05-12
US62/160,411 2015-05-12
US201562269741P 2015-12-18 2015-12-18
US62/269,741 2015-12-18
US201662276072P 2016-01-07 2016-01-07
US62/276,072 2016-01-07

Publications (2)

Publication Number Publication Date
WO2016183366A2 WO2016183366A2 (fr) 2016-11-17
WO2016183366A3 true WO2016183366A3 (fr) 2016-12-29

Family

ID=57248513

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/032188 Ceased WO2016183366A2 (fr) 2015-05-12 2016-05-12 Compositions et méthodes permettant l'extinction de l'expression de l'arn du virus de l'hépatite d

Country Status (1)

Country Link
WO (1) WO2016183366A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
US10245229B2 (en) 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
DK2970456T3 (da) 2013-03-14 2021-07-05 Translate Bio Inc Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer
KR20210122917A (ko) 2013-03-14 2021-10-12 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
PL3467108T3 (pl) 2013-03-14 2024-09-30 Translate Bio, Inc. Sposoby oczyszczania informacyjnego rna
US10130649B2 (en) 2013-03-15 2018-11-20 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
EA034103B1 (ru) 2013-10-22 2019-12-27 Транслейт Био, Инк. СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
PT3134506T (pt) 2014-04-25 2019-10-31 Translate Bio Inc Métodos de purificação de rna mensageiro
WO2017177169A1 (fr) 2016-04-08 2017-10-12 Rana Therapeutics, Inc. Acide nucléique codant multimère et ses utilisations
CA3027312A1 (fr) 2016-06-13 2017-12-21 Translate Bio, Inc. Therapie a base d'arn messager pour le traitement de la carence en ornithine transcarbamylase
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
EP3727428A1 (fr) 2017-12-20 2020-10-28 Translate Bio, Inc. Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
JP7432929B2 (ja) * 2018-05-31 2024-02-19 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途
CA3108544A1 (fr) 2018-08-24 2020-02-27 Translate Bio, Inc. Procedes de purification d'arn messager
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050058982A1 (en) * 2002-07-26 2005-03-17 Chiron Corporation Modified small interfering RNA molecules and methods of use
US20050170337A1 (en) * 1998-07-02 2005-08-04 President And Fellows Of Harvard College Oligomerization of hepatitis delta antigen
US20140248338A1 (en) * 2011-10-05 2014-09-04 Protiva Biotherapeutics, Inc. Compositions and methods for silencing aldehyde dehydrogenase
WO2015054451A1 (fr) * 2013-10-09 2015-04-16 The United States Of America As Represented By The Secretary Department Of Health And Human Services Détection du virus de l'hépatite delta (vhd) pour le diagnostic et le traitement du syndrome de sjögren et du lymphome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050170337A1 (en) * 1998-07-02 2005-08-04 President And Fellows Of Harvard College Oligomerization of hepatitis delta antigen
US20050058982A1 (en) * 2002-07-26 2005-03-17 Chiron Corporation Modified small interfering RNA molecules and methods of use
US20140248338A1 (en) * 2011-10-05 2014-09-04 Protiva Biotherapeutics, Inc. Compositions and methods for silencing aldehyde dehydrogenase
WO2015054451A1 (fr) * 2013-10-09 2015-04-16 The United States Of America As Represented By The Secretary Department Of Health And Human Services Détection du virus de l'hépatite delta (vhd) pour le diagnostic et le traitement du syndrome de sjögren et du lymphome

Also Published As

Publication number Publication date
WO2016183366A2 (fr) 2016-11-17

Similar Documents

Publication Publication Date Title
WO2017019891A3 (fr) Compositions et méthodes de silençage de l'expression du gène du virus de l'hépatite b
WO2016183366A3 (fr) Compositions et méthodes permettant l'extinction de l'expression de l'arn du virus de l'hépatite d
PH12017500614A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
WO2016154127A3 (fr) Compositions et méthodes pour traiter l'hypertriglycéridémie
WO2017027350A3 (fr) Thérapie par interférence arn pour l'infection par le virus de l'hépatite b
EP4233898A3 (fr) Vaccins contre l'arnm de la grippe
EP4299754A3 (fr) Procédés et compositions permettant une délivrance efficace d'acides nucléiques et d'antimicrobiens à base d'arn
EP4647079A3 (fr) Compositions d'arni contre le virus de l'hépatite b (vhb) et leurs procédés d'utilisation
MX2022016376A (es) Oligonucleotidos para inducir la expresion paterna de la ligasa de la proteina ubiquitina e3a (ube3a).
JOP20170161A1 (ar) عوامل RNAi للعدوى بفيروس التهاب الكبد ب
MX377162B (es) Nuevas enzimas y sistemas crispr
EP4632075A3 (fr) Procédé de réduction de l'immunogénicité d'arn
WO2015042308A3 (fr) Inhibiteurs du vih à base d'arn
MD4760B1 (ro) Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
EP4454637A3 (fr) Traitement de la dégénérescence maculaire liée à l'âge à l'aide de complexes d'arn qui ciblent myd88 ou tlr3
CY1125031T1 (el) Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης
WO2015123592A3 (fr) Particules d'arn recombiné et méthodes d'utilisation
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
MY184269A (en) Broad-spectrum anti-influenza virus therapeutic peptides
TH1901000740A (th) สาร rnai สำหรับการติดเชื้อไวรัสตับอักเสบ b
JO3769B1 (ar) علاج RNAi لعدوى فيروس التهاب الكبد B
MA40218A (fr) Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d
TH168570A (th) วิธีการของการเตรียมนิวคลิโอไทด์อนาล็อกที่ถูกแทนที่

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16793557

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16793557

Country of ref document: EP

Kind code of ref document: A2